● Recruiting

ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)

Condition: Non Small Cell Lung Cancer · Liquid Biopsy · Tyrosine Kinase Inhibitor · Sponsor: Erasmus Medical Center

PhaseN/A

Planned participants1300

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis.

This description comes directly from the study's public registry record.

Talk to the study team

Anne-Marie Dingemans, MD, PhD · +31107040704 · a.dingemans@erasmusmc.nl

Always discuss trial participation with your own doctor first.

Locations (1)

Erasmus MC

Rotterdam, Netherlands

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05221372